Dr. Ross is the Director of the Center for Vaccines and Immunology and Professor in Infectious Diseases at the University of Georgia. He is the Georgia Research Alliance Eminent Scholar in Influenza and Emerging Pathogens. He is a scientist with experience in the fields of virology, vaccines, immunology, and microbiology. Dr. Ross’ research focuses on designing, developing and testing vaccines for viral diseases such as influenza, and other viruses. He is the senior investigator that developed computationally-optimized broadly reactive antigen (COBRA) technology for the universal, rational design of vaccine candidates for influenza viruses. He is the primary investigator on 20 years of continuously externally funded research projects from the National Institutes of Health, National Science Foundation, Sanofi-Pasteur, Department of Defense and PATH Vaccine Solutions/Bill and Melinda Gates Foundation, among others.
He has published more than 130 papers on infectious disease and vaccine development. He is an editorial 100 board member of Vaccine. He previously served as editor in chief of the journal Current HIV Research. In addition, he has been an ad-hoc reviewer on NIH study sections and a reviewer for 14 different journals.
He joined the University of Georgia in 2015 after a stint as Director of Vaccines and Viral Immunity at the Vaccine and Gene Therapy Institute (VGTI) of Florida. Prior to joining VGTI Florida, Dr. Ross was an associate professor at the University of Pittsburgh School of Medicine and a member of its Center for Vaccine Research for 10 years. He conducted postdoctoral research at Emory University's Vaccine Research Center and at Duke University. He holds a doctorate in microbiology and immunology from Vanderbilt University, where he received the inaugural Sidney P. Colowick Outstanding Graduate Award.
He has served as the Treasurer of International Society for Vaccines since 2012, is chair of the ISV Outreach and Membership subcommittees, and he has served as the Co-Chair of the 8th and 9th Vaccine and ISV Congress in Philadelphia (8th) and Seoul (9th).